ArticleImmunology1984
Myeloperoxidase is more efficient than eosinophil peroxidase in the in vitro killing of newborn larvae of Trichinella spiralis.
Article in Immunology, 1984. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 41 citations in OpenAlex.
- The Effect of Helminths on Granulocyte Activation: A Cluster-Randomized Placebo-Controlled Trial in Indonesia.The Journal of infectious diseases · 2019Trial
- A Natural Enzyme GOx-MOF Cascade Complex Killing Zoonotic Parasite Trichinella spiralis by Energy Utilization Limitation and Generated Free Radicals.Transboundary and emerging diseases · 2026Article
- The Roles of Various Immune Cell Populations in Immune Response against Helminths.International journal of molecular sciences · 2023Review
- Elevated Systemic Levels of Eosinophil, Neutrophil, and Mast Cell Granular Proteins inFrontiers in immunology · 2018Article
- Article
- Serglycin proteoglycans limit enteropathy in Trichinella spiralis-infected mice.BMC immunology · 2016Article
- Major basic protein from eosinophils and myeloperoxidase from neutrophils are required for protective immunity to Strongyloides stercoralis in mice.Infection and immunity · 2011Article
- Human eosinophil peroxidase induces surface alteration, killing, and lysis of Mycobacterium tuberculosis.Infection and immunity · 2003Article
- Role of myeloperoxidase in the killing of Naegleria fowleri by lymphokine-altered human neutrophils.Infection and immunity · 1987Article
- Bactericidal action of eosinophils from normal human blood.Infection and immunity · 1986Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Myeloperoxidase (MPO) and eosinophil peroxidase (EPO) catalyse the formation of hypochlorite (OCl-) from chloride ions (OCl-) and hydrogen peroxide (H2O2). OCl- proved to be highly toxic for Trichinella spiralis newborn larvae (NBL) in in vitro assays. Using purified human MPO and EPO it was found that even at neutral pH both enzymes under appropriate conditions are able to kill NBL. The rate at which OCl- is produced is much lower in the EPO- than in the MPO-mediated reaction. This difference in enzymic activity may explain why in the MPO-mediated reaction half the amount of OCl- was sufficient to kill 50% of the NBL, as compared to the EPO-mediated reaction. Purified human eosinophil major basic protein showed excellent OCl- scavenging properties, resulting in a significant decrease in the EPO-mediated NBL killing. Addition of ammonium ions [(NH4)2SO4] to the EPO-mediated reaction increased the NBL killing remarkably. It was concluded that in vitro MPO is more efficient than EPO in killing NBL. Furthermore, it was suggested that although eosinophils show marked parasiticidal effects in various in vitro systems, their primary biological role might be the regulation of the inflammatory reactions.
Indexed as
Identifiers
6321330PMC1454451W2247661657What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.